Authorizing of Immunogenicity of concentrated and purified Newcastle disease virus using downstream processing

References
1. Nidzworski D, Wasilewska E, Smietanka K, Szewczyk B,
Minta Z. Detection and differentiation of Newcastle disease
virus and influenza virus by using duplex real-time PCR, Acta
Biochim Pol. 2015; 260(3):475-80.
2. Alexander DJ. A review of avian influenza in different bird
species.Veterinary Microbiology. 2000; 74, 3-13.
3. Alexander DJ, Aldous EW, Fuller CM. The long view: a
selective review of 40 years of Newcastle disease research.
Avian Pathol. 2012; 41(4):329-35.
4. Alexandr, DJ, Senne DA. Newcastle disease and other avian
paramyxoviruses. L. D. Zavala,ed.Omnipress. 2008; 135-141.
5. Senne D.A., King D.J. & Kapczynski D.R. 2004. Control of
Newcastle disease by vaccinationDev Biol (Basel). 119:165-
70.
6. Assembly of Delegates of the OIE. Avian Influenza.
Paris,France: OIE; 2015
7. Hutchinson E, Fodor E. Purification of influenza virions by
haemadsorption and ultracentrifugation. Protocol Exchange.
2014; 2014: 10.1038.
8. Kalbfuss B, Wolff M, Morenweiser R, Reichl U. Purification
of cell culture-derived human influenza A virus by sizeexclusionand anion-exchange chromatography. Biotechnol
Bioeng. 2007; 96: 932–944.
9. Blanche F, Cameron B, Barbot A, et al. An improved anionexchange HPLC method for the detection and purification of
adenoviral particles. Gene Ther. 2000; 7: 1055–1062.
10. Guo P, El-Gohary Y, Prasadan K, et al. Rapid and
simplifiedpurification of recombinant adeno-associated virus. J
VirolMethods. 2012; 183: 139–146.
11. Heyward JT, Klimas RA, Stapp MD, Obijeski JF. The rapid,
concentration and purification of influenza virus from allantoic
fluid. Arch Virol. 1977; 55: 107–11911, 17.
12. Xiangpeng R, Chunyi X, Qingming K, Chengwen Z.
Proteomic analysis of purified Newcastle disease virus
particles. Proteome Science. 2012; 10:32.
13. McGinnes L.W., Pantua H., Reitter J., Morrison T.G.
Newcastle disease virus: propagation, quantification, and
storage. Curr. Protoc. Microbiol. 2006; Chapter 15 Unit
15F.12.
14. Ungerechts G., Bossow S., Leuchs B., Holm P.S.,
Rommelaere J., Coffey M., Coffin R., Bell J., Nettelbeck D.M.
Moving oncolytic viruses into the clinic: clinical-grade
production, purification, and characterization of diverse
oncolytic viruses. Mol. Ther. Methods Clin. Dev. 2016;
3:16018.
15. Vicente T., Mota J.P., Peixoto C., Alves P.M., Carrondo
M.J. Rational design and optimization of downstream
processes of virus particles for biopharmaceutical applications:
current advances. Biotechnol. Adv. 2011; 29:869–878.
16. Ebrahimi MM, Moghaddampour M, Tavassoli A,
Shahsavandi S. Vaccination of chicks with experimental
Newcastle disease and avian influenza oil-emulsion vaccines
by in ovo inoculation. Archives of Razi Institute. 2000; 51:
15–25.
17. Bradford MM. A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal Biochem 1976; 72:
248–254.
18. Allan WH, Gough RE. A standard hemagglutination
inhibition test for Newcastle disease.Vaccination and
challenge. Vet Rec. 1974; 95 (7):147-149.
19. Laemmli UK. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature. 1970; 227:
680–685.
20. Morenweiser R. Downstream processing of viral vectors
and vaccines, Gene Therapy. 2005; 12, S103–S110.
21. WHO Technical Report Series No. 927 (2005).
22. Mayo MA. A summary of taxonomic changes recently
approved by ICTV. Arch Virol. 2002 Aug; 147(8):1655-63.
doi: 10.1007/s007050200039.
23. Gallili GE, Ben-Nathan D. Newcastle disease vaccines.
Biotechnol Adv. 1998 Mar; 16(2):343-66. doi: 10.1016/s0734-
9750(97)00081-5.
24. Kramberger P, Urbas L, Štrancar A. Downstream
processing and chromatography based analytical methods for
production of vaccines, gene therapy vectors, and
bacteriophages. Human Vaccines & Immunotherapeutics.
2015; 11:4, 1010-1021.
25. Payal A, Lakhchaura BD, Grang SK. Evaluation of
immunogenic potential of 75 kDa and 56 kDa proteins of
Newcastle disease virus (NDV), Indian Journal of
Experimental Biology. 2010; 48, 889-895.
26. Reimer CB, Baker RS, van Frank RM, Newlin TE.
Purification of large quantities of influenza, virus by density
gradient centrifugation. J Virol. 1967; 1: 1207–1216.
27. DiNapoli JM, Yang L, Suguitan A Jr, Elankumaran S,
Dorward DW, Murphy BR, Samal SK, Collins PL, Bukreyev
A. Immunization of primates with a Newcastle disease virusvectored vaccine via the respiratory tract induces a high titer of
Nazari et al / Archives of Razi Institute, Vol. 79, No. 1 (2024) 109-117 117
serum neutralizing antibodies against highly pathogenic avian
influenza virus. J Virol. 2007 Nov; 81(21):11560-8.
28. Terrier O, Rolland JP, Rosa-Calatrava M, Lina B, Thomas
D, Moules V. Parainfluenza virus type 5 (PIV-5) morphology
revealed by cryo-electron microscopy. Virus Res. 2009 Jun;
142(1-2):200-3.
29. Goff PH, GAO Q, Palese P. A majority of infectious
Newcastle disease virus particles contain a single genome,
while a minority contain multiple genomes. J Virol. 2012 Oct;
86(19):10852-6.
30. Macpherson LW. Electron-Microscope Studies of the Virus
of Newcastle Disease. Can J Comp Med Vet Sci. 1956 Mar;
20(3):72-8.
31. Nazari shirvan A, Samianifar M, Ghodsian N. Purification
of avian influenza virus (H9N2) from allantoic fluid by sizeexclusion chromatography, Turk J Vet Anim Sci. 2016;
40:1506-8.
32. Loa CC, Lin TL, Wu CC, Bryan TA, Thacker HL, Hooper
T, et al. Purification of turkey coronavirus by Sephacryl sizeexclusion chromatography. J Virol Methods. 2002; 104: 187–
194.
33. Nayak DP, Lehmann S, Reichel U. Downstream processing
of MDCK cell-derived equine influenza virus. J Chromatogr
B. 2005; 823: 75–81.
34. Ernawati R, Ibrahim AL. Newcastle disease vaccination in
Malaysia: application of oil emulsion vaccine. Vet
Microbiol. 1995; 46(1-3):69-77.
35. Reed, L.J. Muench, H. (1938). A simple method of
estimating fifty percent endpoints. American Journal of
Hygiene 27:493-497.